EISAI CO
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 1941-12-06
- Employees
- 11K
- Market Cap
- $12B
- Website
- http://www.eisai.co.jp
A Study to Assess the Safety and Tolerability of E8001 in Healthy Male Participants
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT04609852
- Locations
- 🇯🇵
Eisai Trial Site #1, Minato-ku, Japan
A Study to Evaluate the Safety of DAYVIGO (Lemborexant) Tablets in Participants With Insomnia.
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 550
- Registration Number
- NCT04573556
- Locations
- 🇯🇵
Eisai trial site 1, Nagoya, Japan
🇯🇵Eisai trial site 3, Tokyo, Japan
🇯🇵Eisai trial site 2, Osaka, Japan
A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-10-01
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT04572295
- Locations
- 🇯🇵
Eisai Trial Site 10, Kitaadachi-gun, Saitama, Japan
🇯🇵Eisai Trial Site 2, Shinagawa-ku, Tokyo, Japan
🇯🇵Eisai Trial Site 6, Kashiwa, Chiba, Japan
Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-09-29
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 33
- Registration Number
- NCT04568902
- Locations
- 🇯🇵
Eisai Trial Site 2, Chuo Ku, Japan
🇯🇵Eisai Trial Site 1, Koto-Ku, Japan
A Study to Assess the Effect of Food Intake and Drug-drug Interactions of E7090 When Co-administered With Rabeprazole or Rifampin in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2021-11-01
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT04565574
- Locations
- 🇯🇵
Eisai trial site #1, Minato-ku, Tokoyo, Japan
A Single and Multiple Dose Study of Lemborexant in Healthy Chinese Participants
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2021-07-19
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 26
- Registration Number
- NCT04555733
- Locations
- 🇨🇳
Xuhui Central Hospital, Shanghai, China
A Study of Lemborexant in Chinese Participants With Insomnia Disorder
- Conditions
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 194
- Registration Number
- NCT04549168
- Locations
- 🇨🇳
Beijing Tiantan Hosptial, Capital Medical University, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04271488
- Locations
- 🇯🇵
Eisai Trial Site #5, Kofu, Yamanashi, Japan
🇯🇵Eisai Trial Site #4, Kurume, Fukuoka, Japan
🇯🇵Eisai Trial Site #2, Yufu, Oita, Japan
A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion
- First Posted Date
- 2020-01-23
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 63
- Registration Number
- NCT04238715
- Locations
- 🇯🇵
Eisai Trial Site 20, Kagoshima, Japan
🇯🇵Eisai Trial Site 16, Kashiwa, Chiba, Japan
🇯🇵Eisai Trial Site 15, Fukuoka, Japan
A Study to Evaluate the Safety and Efficacy of Fycompa® (Perampanel) as Add-on Therapy in Participants With Epilepsy
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 117
- Registration Number
- NCT04230044